Cargando…
The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exerci...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461029/ https://www.ncbi.nlm.nih.gov/pubmed/34558218 http://dx.doi.org/10.14814/phy2.15030 |
_version_ | 1784571888681353216 |
---|---|
author | Sadredini, Mani Manotheepan, Ravinea Lehnart, Stephan E. Anderson, Mark E. Sjaastad, Ivar Stokke, Mathis K. |
author_facet | Sadredini, Mani Manotheepan, Ravinea Lehnart, Stephan E. Anderson, Mark E. Sjaastad, Ivar Stokke, Mathis K. |
author_sort | Sadredini, Mani |
collection | PubMed |
description | Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exercise training prevents arrhythmias in CPVT1, potentially by reducing the oxidation of Ca(2+)/calmodulin‐dependent protein kinase type II (CaMKII). Therefore, we tested whether an oxidation‐resistant form of CaMKII protects mice carrying the CPVT1‐causative mutation RyR2‐R2474S (RyR2‐RS) against arrhythmias. Antioxidant treatment (N‐acetyl‐L‐cysteine) reduced the frequency of β‐adrenoceptor stimulation‐induced arrhythmogenic Ca(2+) waves in isolated cardiomyocytes from RyR2‐RS mice. To test whether the prevention of CaMKII oxidation exerts an antiarrhythmic effect, mice expressing the oxidation‐resistant CaMKII‐MM281/282VV variant (MMVV) were crossed with RyR2‐RS mice to create a double transgenic model (RyR2‐RS/MMVV). Wild‐type mice served as controls. Telemetric ECG surveillance revealed an increased incidence of ventricular tachycardia and an increased arrhythmia score in both RyR2‐RS and RyR2‐RS/MMVV compared to wild‐type mice, both following a β‐adrenoceptor challenge (isoprenaline i.p.), and following treadmill exercise combined with a β‐adrenoceptor challenge. There were no differences in the incidence of arrhythmias between RyR2‐RS and RyR2‐RS/MMVV mice. Furthermore, no differences were observed in β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS/MMVV compared to RyR2‐RS. In conclusion, antioxidant treatment reduces β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS cardiomyocytes. However, oxidation‐resistant CaMKII‐MM281/282VV does not protect RyR2‐RS mice from β‐adrenoceptor stimulation‐induced Ca(2+) waves or arrhythmias. Hence, alternative oxidation‐sensitive targets need to be considered to explain the beneficial effect of antioxidant treatment on Ca(2+) waves in cardiomyocytes from RyR2‐RS mice. |
format | Online Article Text |
id | pubmed-8461029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84610292021-09-28 The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 Sadredini, Mani Manotheepan, Ravinea Lehnart, Stephan E. Anderson, Mark E. Sjaastad, Ivar Stokke, Mathis K. Physiol Rep Original Articles Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exercise training prevents arrhythmias in CPVT1, potentially by reducing the oxidation of Ca(2+)/calmodulin‐dependent protein kinase type II (CaMKII). Therefore, we tested whether an oxidation‐resistant form of CaMKII protects mice carrying the CPVT1‐causative mutation RyR2‐R2474S (RyR2‐RS) against arrhythmias. Antioxidant treatment (N‐acetyl‐L‐cysteine) reduced the frequency of β‐adrenoceptor stimulation‐induced arrhythmogenic Ca(2+) waves in isolated cardiomyocytes from RyR2‐RS mice. To test whether the prevention of CaMKII oxidation exerts an antiarrhythmic effect, mice expressing the oxidation‐resistant CaMKII‐MM281/282VV variant (MMVV) were crossed with RyR2‐RS mice to create a double transgenic model (RyR2‐RS/MMVV). Wild‐type mice served as controls. Telemetric ECG surveillance revealed an increased incidence of ventricular tachycardia and an increased arrhythmia score in both RyR2‐RS and RyR2‐RS/MMVV compared to wild‐type mice, both following a β‐adrenoceptor challenge (isoprenaline i.p.), and following treadmill exercise combined with a β‐adrenoceptor challenge. There were no differences in the incidence of arrhythmias between RyR2‐RS and RyR2‐RS/MMVV mice. Furthermore, no differences were observed in β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS/MMVV compared to RyR2‐RS. In conclusion, antioxidant treatment reduces β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS cardiomyocytes. However, oxidation‐resistant CaMKII‐MM281/282VV does not protect RyR2‐RS mice from β‐adrenoceptor stimulation‐induced Ca(2+) waves or arrhythmias. Hence, alternative oxidation‐sensitive targets need to be considered to explain the beneficial effect of antioxidant treatment on Ca(2+) waves in cardiomyocytes from RyR2‐RS mice. John Wiley and Sons Inc. 2021-09-23 /pmc/articles/PMC8461029/ /pubmed/34558218 http://dx.doi.org/10.14814/phy2.15030 Text en © 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Sadredini, Mani Manotheepan, Ravinea Lehnart, Stephan E. Anderson, Mark E. Sjaastad, Ivar Stokke, Mathis K. The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title | The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title_full | The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title_fullStr | The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title_full_unstemmed | The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title_short | The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 |
title_sort | oxidation‐resistant camkii‐mm281/282vv mutation does not prevent arrhythmias in cpvt1 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461029/ https://www.ncbi.nlm.nih.gov/pubmed/34558218 http://dx.doi.org/10.14814/phy2.15030 |
work_keys_str_mv | AT sadredinimani theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT manotheepanravinea theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT lehnartstephane theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT andersonmarke theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT sjaastadivar theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT stokkemathisk theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT sadredinimani oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT manotheepanravinea oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT lehnartstephane oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT andersonmarke oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT sjaastadivar oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 AT stokkemathisk oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1 |